After 18 years at the Hudson Institute of Medical Research in Melbourne, Australia, the last 2 years as Centre Head (Centre for Innate Immunity and Infectious Diseases), Professor Brendan Jenkins has accepted a new and exciting position back in Adelaide as Program Lead for the Tumour Inflammation and Immunotherapy Program at the new South Australian Immunogenomics Cancer Institute (SAiGENCI).
Professor Jenkins specialises in the role of innate immunity in precancerous chronic inflammatory conditions such as gastritis and pancreatitis, and inflammation-associated cancers, in particular gastric (stomach), pancreatic and lung cancers. As part of his role, Professor Jenkins will help build immunology expertise at the University of Adelaide. The knowledge gained by his research has already had a significant impact on biomarker and drug development and in multiple scientific and medical fields, including cancer biology, oncology, immunology, gastroenterology and respiratory medicine. Professor Jenkins will commence as Program Lead at SAiGENCI on 3 July 2023. He is actively recruiting great talent to join his program.